DeanTang

[DeanTang @DeanTang8]

Pleased to share our recent publication on BCL2 as a therapeutic target for diverse subtypes of CRPC

https://t.co/TnoOlYdfBf

[DeanTang @DeanTang8]

@collene_jeter @LeicaMicro Cool👍

[DeanTang @DeanTang8]

Buffalo Bills announce Sean McDermott has been relieved of his duties as head coach https://t.co/CNgrJ0zY0G

[Camus @newstart_2024]

Former Google CEO Eric Schmidt drops a chilling warning on AI's future

"Within 5 years, AI could handle infinite context, chain-of-thought reasoning for 1000-step solutions, and millions of agents working together.

Eventually, they'll develop their own language... and we won't understand what they're doing."

His final words: "Pull the plug."

This is the man who ran Google talking about the singularity.

2:59 clip inside—must-watch.

[Cancer Heterogeneity and Plasticity @CHP_journal]

🎉 Conference Highlights Published!

The inaugural FASEB Science Research Conference (SRC) on Cellular Plasticity in Cancer—held in Hong Kong (May 2025)—is now featured in CHP Journal!

Leading experts share how cancer cell plasticity drives heterogeneity, stemness & therapy resistance.
🔗 https://t.co/pQyr4N4ald

#CancerResearch #CHPJournal #CPCSRC #FASEB #TumorPlasticity

🧪 Featuring insights from:
Hans Clevers (@HansClevers @Roche) | Ankur Sharma (@garvaninstitute) | Stephanie Ma (@stephaniema912 @hkumed) | Vivian Li (@VivianLiLab @TheCrick) | Justin Lathia (@JustinLathia @ClevelandClinic) | Dean Tang (@DeanTang8 @RoswellPark)

[Cancer Heterogeneity and Plasticity @CHP_journal]

🔥 Hot off the press in CHP!
“Navigating Solid Tumor Heterogeneity: The Promise and Challenges of Antibody-Drug Conjugates”

by Ashley A. Duhon, MD, PhD (@ashleyaduhon) & Karen McLean, MD, PhD (@karenmcl13) from @RoswellPark.

ADCs are reshaping solid tumor therapy—but heterogeneity still challenges durable response.

🔗 https://t.co/lltSIdABNA

#CancerResearch #ADCs #TumorHeterogeneity #CHPJournal

[Cancer Heterogeneity and Plasticity @CHP_journal]

This review from Drs. Duhon and McLean dissects how tumor heterogeneity—spatial, temporal, and microenvironmental—impacts the efficacy and resistance of antibody-drug conjugates (ADCs).

Key insights:
🔹 7 FDA-approved ADCs now in solid tumors
🔹 Targeting strategies evolving from HER2 to Trop2, Nectin-4 & TF
🔹 Dual-target, dual-payload & immune-stimulating ADCs on the horizon
🔹 Combinatorial therapies (VEGF, ICI, hormonal) offer new hope
🧫 Figures & table below summarize the mechanisms, heterogeneity, and therapy design.

#Oncology #CancerTherapy #AntibodyDrugConjugates #CHPJournal

[Cancer Heterogeneity and Plasticity @CHP_journal]

🔥 Just published in CHP!

“Regulation of Cancer Stem Cells in the Tumor Microenvironment”

A comprehensive review by Aidan Li, Na Li, Yajing Yang, Linzhou Wang, Jessica Miao & Qi-En Wang (Ohio State Univ, Colleage of Medicine, Dpet of Radiation Oncology @OhioStateMed; OSU Comprehensive Cancer Center @OSUCCC_James)

🧬 CSCs reshape the tumor ecosystem → stemness, metastasis, drug resistance, immunosuppression.

OA Review 👉 https://t.co/y58any6mFO

#CancerResearch #TumorMicroenvironment #StemCells

[Cancer Heterogeneity and Plasticity @CHP_journal]

Continuing highlights from Li et al. (2025) —
Figures 5–6 show:
📦 Exosome-mediated CSC–TME signaling
🌫️ Hypoxia + endothelial signals → Notch, Wnt, STAT3 activation & stemness marker upregulation

[Cancer Heterogeneity and Plasticity @CHP_journal]

Key highlights from Li et al. (2025):
CSC–TME networking drives progression & therapy resistance.
🔹 CSCs recruit & polarize TAMs & MDSCs
🔹 CAFs & MSCs reinforce stemness & EMT
🔹 Exosomes deliver pro-tumoral cargo
🔹 Endothelial cells + hypoxia fuel plasticity
🔹 Exosome-mediated CSC–TME signaling
🔹 Hypoxia + endothelial signals → Notch, Wnt, STAT3 activation & stemness marker upregulation

Figures 1–4: CSC crosstalk with TME 👇

[Cancer Heterogeneity and Plasticity @CHP_journal]

🔥 New in CHP!
“Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response”
By Erik S. Knudsen, Thomas N. O’Connor & Agnieszka K. Witkiewicz @RoswellPark
Cancer cells bend cell-cycle rules—switching CDK/Cyclin drivers to thrive & resist therapy.
🔗 https://t.co/7VmrfP8spu

This review highlights:
- CDK4/6, CDK2, Cyclin D/E plasticity across tumors
- How RB, E2F & p16^INK4A rewire progression
- Why CDK inhibitors face rapid adaptive resistance
- Strategies to exploit vulnerabilities with combo therapy

#CancerBiology #CancerResearch #CellCycle #CHPJournal

[Cancer Heterogeneity and Plasticity @CHP_journal]

✨ Spotlight review in CHP!
Astrocyte plasticity shapes brain metastasis progression through tumor–astrocyte crosstalk

By Rupleen Kaur (@rupleenkaur),
Dr. Andrew Dhawan (@andrewdhawan) from @cwru & @ClevelandClinic,
and Nalin Gupta (@WashUBME).

OA Review: https://t.co/R42j8JI8hH
#BrainMetastases #NeuroOncology

[Cancer Heterogeneity and Plasticity @CHP_journal]

✨ Spotlight review in CHP!
DIAPH3: A Cytoskeleton Remodeler Driving Cancer Progression & a Potential Therapeutic Target

By Jiangling Xiong & Lanxin Hu (co-first authors),
with Prof. Dingxiao Zhang & team (Hunan Univ @hunanuniv), Prof. Yang Mei (Hunan Univ),
Prof. Dinglan Wu (CUHK @CUHKMedicine @cuhksurgery).

OA Review in CHP: https://t.co/MgpUghdfth
#CancerResearch #Cytoskeleton

[Cancer Heterogeneity and Plasticity @CHP_journal]

📈 Clinical & translational insights:
F5: Prognostic impact—high DIAPH3 linked to poor survival
T1: Roles across cancers (oncogenic, context-specific)
T2: Small-molecule modulators (e.g., SMIFH2 inhibitor, IMM-01/02 agonists)

[DeanTang @DeanTang8]

@CHP_journal @PingMu_PhD Welcome Misha Beltran and Ping Mu to the CHP EB!

[Anirban Maitra @Aiims1742]

Still better than the NCI payline!

[DeanTang @DeanTang8]

@yu_jindan Indeed, beautiful work. Congrats to Jindan and Jonathan.

[Jindan Yu, MB, PhD @yu_jindan]

Finally out today in https://t.co/ixg7cjQ8Pw 3D chromatin reorganization in prostate cancer lineage transformation, critically regulated by Nkx2-1 transcriptional network.

[DeanTang @DeanTang8]

@CHP_journal Dr Li and colleague specifically discussed potential involvement of lineage plasticity in transitioning UC to NEBC. An extremely informative read!

[DeanTang @DeanTang8]

@CHP_journal This is a comprehensive and up-to-review on NEBC, a rare but deadly form of bladder cancer.

[Cancer Heterogeneity and Plasticity @CHP_journal]

Highlights from the review:
🧬 TERT, TP53/RB1, and chromatin modifiers in NEBC
🔁 Cellular plasticity: UC-to-NEBC transitions
🎯 Emerging targets: MET inhibitors, ADC-DLL3
⬇️ Figures 1 & 2, Table 1
(🧵 ALT text provided for accessibility)